Nuevolution to present new data on its BET BD1 program supporting effect in Psoriasis/Atopic Dermatitis
Stockholm, 27 November 2017. Nuevolution AB (publ) (NUE.ST) today announced that Thomas Franch, Chief Scientific Officer, will be presenting new data on Nuevolution’s selective bromodomain BET BD1 inhibitor at the Global Medicinal Chemistry and GPCR Summit, held on 27-28 November in London, UK.
At the conference, new data on Nuevolution’s selective bromodomain BET BD1 inhibitor, NUE7770, will be presented. This includes preliminary data from an IL23-induced mouse model relevant for potential applications in human diseases such as Psoriasis or Atopic Dermatitis. The data support efficacy of NUE7770 on ear edema scoring and on reduction of IL22 levels. A further study is now under way to improve understanding of the mechanism-of-action and to help guide Nuevolution’s conclusion regarding its choice of optimal indication(s) for the further development of the program.
Dr. Franch will be presenting these new data in the context of previously disclosed data from Nuevolution’s selective bromodomain BET BD1 selective inhibitor program (inflammation and auto-immune diseases) showing in-vitro / in-vivo efficacies and good safety data for NUE7770 and related program compounds.
The potent and BET BD1 selective compounds in this program was originally identified using Nuevolution’s proprietary Chemetics® technology, and the program is currently in pre-clinical development for potential application in multiple inflammatory and autoimmune diseases.
For more information, please contact:
Thomas Franch, CSO
Phone: +45 7020 0987
Henrik D. Simonsen, CFO
Phone: +45 3913 0947
The Nuevolution Chemetics™ platform technology comprises proprietary methods enabling DNA-encoding of compound libraries for fast and cost-efficient screening of disease targets. Nuevolution annually produces up to eight Chemetics™ libraries. For further details see Nuevolution homepage: www.nuevolution.com.
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.[AG1] The information was sent for publication, through the agency of the contact persons set out above, on Monday 27 November 2017, 12:00 CET.
Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at: www.nuevolution.com.
[AG1]To be discussed and confirmed